528 related articles for article (PubMed ID: 29968252)
21. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
[TBL] [Abstract][Full Text] [Related]
22. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
[TBL] [Abstract][Full Text] [Related]
23. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
24. Chromosome 5q loss in colorectal flat adenomas.
Voorham QJ; Carvalho B; Spiertz AJ; van Grieken NC; Mongera S; Rondagh EJ; van de Wiel MA; Jordanova ES; Ylstra B; Kliment M; Grabsch H; Rembacken BJ; Arai T; de Bruïne AP; Sanduleanu S; Quirke P; Mulder CJ; van Engeland M; Meijer GA
Clin Cancer Res; 2012 Sep; 18(17):4560-9. PubMed ID: 22761468
[TBL] [Abstract][Full Text] [Related]
25. Identification of an intermediate signature that marks the initial phases of the colorectal adenoma-carcinoma transition.
Tang H; Guo Q; Zhang C; Zhu J; Yang H; Zou YL; Yan Y; Hong D; Sou T; Yan XM
Int J Mol Med; 2010 Nov; 26(5):631-41. PubMed ID: 20878084
[TBL] [Abstract][Full Text] [Related]
26. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
[TBL] [Abstract][Full Text] [Related]
27. RNA-Seq-Based Molecular Classification Analyses in Colorectal Cancer and Synchronous Adenoma.
Choi JW; Lee GY; Kim S; Ahn K; Do IG; Jung KU; Kim HO; Kim H; Park DI; Park SK
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835545
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Cancer-Associated DNA Copy Number Events in Colorectal (Advanced) Adenomas.
Carvalho B; Diosdado B; Terhaar Sive Droste JS; Bolijn AS; Komor MA; de Wit M; Bosch LJW; van Burink M; Dekker E; Kuipers EJ; Coupé VMH; van Grieken NCT; Fijneman RJA; Meijer GA
Cancer Prev Res (Phila); 2018 Jul; 11(7):403-412. PubMed ID: 29685877
[TBL] [Abstract][Full Text] [Related]
29. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J
Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112
[TBL] [Abstract][Full Text] [Related]
30. Genome-wide expression profiling in colorectal cancer focusing on lncRNAs in the adenoma-carcinoma transition.
Kalmár A; Nagy ZB; Galamb O; Csabai I; Bodor A; Wichmann B; Valcz G; Barták BK; Tulassay Z; Igaz P; Molnár B
BMC Cancer; 2019 Nov; 19(1):1059. PubMed ID: 31694571
[TBL] [Abstract][Full Text] [Related]
31. Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer.
Luo Y; Wong CJ; Kaz AM; Dzieciatkowski S; Carter KT; Morris SM; Wang J; Willis JE; Makar KW; Ulrich CM; Lutterbaugh JD; Shrubsole MJ; Zheng W; Markowitz SD; Grady WM
Gastroenterology; 2014 Aug; 147(2):418-29.e8. PubMed ID: 24793120
[TBL] [Abstract][Full Text] [Related]
32. Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype.
Kwon Y; Park M; Jang M; Yun S; Kim WK; Kim S; Paik S; Lee HJ; Hong S; Kim TI; Min B; Kim H
Oncotarget; 2017 Jun; 8(24):39367-39381. PubMed ID: 28455965
[TBL] [Abstract][Full Text] [Related]
33. The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
Marisa L; Svrcek M; Collura A; Becht E; Cervera P; Wanherdrick K; Buhard O; Goloudina A; Jonchère V; Selves J; Milano G; Guenot D; Cohen R; Colas C; Laurent-Puig P; Olschwang S; Lefèvre JH; Parc Y; Boige V; Lepage C; André T; Fléjou JF; Dérangère V; Ghiringhelli F; de Reynies A; Duval A
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922790
[TBL] [Abstract][Full Text] [Related]
34. Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer.
Dunne PD; O'Reilly PG; Coleman HG; Gray RT; Longley DB; Johnston PG; Salto-Tellez M; Lawler M; McArt DG
Oncotarget; 2016 Jun; 7(24):36632-36644. PubMed ID: 27153559
[TBL] [Abstract][Full Text] [Related]
35. Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies.
Alderdice M; Richman SD; Gollins S; Stewart JP; Hurt C; Adams R; McCorry AM; Roddy AC; Vimalachandran D; Isella C; Medico E; Maughan T; McArt DG; Lawler M; Dunne PD
J Pathol; 2018 May; 245(1):19-28. PubMed ID: 29412457
[TBL] [Abstract][Full Text] [Related]
36. A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues.
de Back TR; Wu T; Schafrat PJ; Ten Hoorn S; Tan M; He L; van Hooff SR; Koster J; Nijman LE; Vink GR; Beumer IJ; Elbers CC; Lenos KJ; Sommeijer DW; Wang X; Vermeulen L
Life Sci Alliance; 2024 Aug; 7(8):. PubMed ID: 38782602
[TBL] [Abstract][Full Text] [Related]
37. Functionally-focused algorithmic analysis of high resolution microarray-CGH genomic landscapes demonstrates comparable genomic copy number aberrations in MSI and MSS sporadic colorectal cancer.
Ali H; Bitar MS; Al Madhoun A; Marafie M; Al-Mulla F
PLoS One; 2017; 12(2):e0171690. PubMed ID: 28231327
[TBL] [Abstract][Full Text] [Related]
38. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.
Linnekamp JF; Hooff SRV; Prasetyanti PR; Kandimalla R; Buikhuisen JY; Fessler E; Ramesh P; Lee KAST; Bochove GGW; de Jong JH; Cameron K; Leersum RV; Rodermond HM; Franitza M; Nürnberg P; Mangiapane LR; Wang X; Clevers H; Vermeulen L; Stassi G; Medema JP
Cell Death Differ; 2018 Mar; 25(3):616-633. PubMed ID: 29305587
[TBL] [Abstract][Full Text] [Related]
39. Gene-dosage dependent overexpression at the 13q amplicon identifies DIS3 as candidate oncogene in colorectal cancer progression.
de Groen FL; Krijgsman O; Tijssen M; Vriend LE; Ylstra B; Hooijberg E; Meijer GA; Steenbergen RD; Carvalho B
Genes Chromosomes Cancer; 2014 Apr; 53(4):339-48. PubMed ID: 24478024
[TBL] [Abstract][Full Text] [Related]
40. Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study.
González-Montero J; Burotto M; Valenzuela G; Mateluna D; Buen-Abad F; Toro J; Barajas O; Marcelain K
World J Clin Oncol; 2023 Oct; 14(10):409-419. PubMed ID: 37970108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
